Keele Research Repository

Article

Quirke-McFarlane, S, Weinman, J, Cook, ES, Yiu, ZZN, Dand, N, Langan, SM, Bechman, K, Tsakok, T, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Barbosa, IA, Bachelez, H, Capon, F, Contreras, CR, De La Cruz, C, Di Meglio, P, Gisondi, P, Jullien, D, Lambert, J, Naldi, L, Puig, L, Spuls, P, Torres, T, Warren, RB, Waweru, H, Galloway, JB, Griffiths, CEM, Barker, JN, Norton, S, Smith, CH, Mahil, SK and study group, PsoProtect (2022) Non-adherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. British Journal of Dermatology.

Cordingley, L, Nelson, PA, Davies, L, Ashcroft, D, Bundy, C, Chew-Graham, CA ORCID: https://orcid.org/0000-0002-9722-9981, Chisholm, A, Elvidge, J, Hamilton, M, Hilton, R, Kane, K, Keyworth, C, Littlewood, A, Lovell, K, Lunt, M, McAteer, H, Ntais, D, Parisi, R, Pearce, C, Rutter, M, Symmons, D, Young, H and Griffiths, CEM (2022) Identifying and managing psoriasis-associated comorbidities: the IMPACT research programme. Programme Grants for Applied Research, 10 (3). 1 - 240.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Burden, AD, Barker, JNWN, Lunt, M, Ali, H, Kleyn, CE, McElhone, K, Soliman, MM, Green, AC, Griffiths, CEM, Reynolds, NJ and Ormerod, AD (2021) Risks of basal cell and squamous cell carcinoma in psoriasis patients after treatment with biologic vs non‐biologic systemic therapies. Journal of the European Academy of Dermatology and Venereology.

Mahil, SK, Yates, M, Langan, SM, Yiu, ZZN, Tsakok, T, Dand, N, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, McAteer, H, Meynell, F, Coker, B, Vincent, A, Urmston, D, Vesty, A, Kelly, J, Lancelot, C, Moorhead, L, Bachelez, H, Bruce, IN, Capon, F, Contreras, CR, Cope, AP, De La Cruz, C, Di Meglio, P, Gisondi, P, Hyrich, K, Jullien, D, Lambert, J, Marzo-Ortega, H, McInnes, I, Naldi, L, Norton, S, Puig, L, Sengupta, R, Spuls, P, Torres, T, Warren, RB, Waweru, H, Weinman, J, Griffiths, CEM, Barker, JN, Brown, MA, Galloway, JB, Smith, CH and CORE-UK study groups, PsoProtect (2021) Risk-mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. British Journal of Dermatology.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis: A Study From the British Association of Dermatologists Biologics and Immunomodulators Register. JAMA Dermatology.

Mahil, SK, Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Dand, N, Coker, B, Wall, D, Fletcher, G, Bosma, A, Capon, F, Iversen, L, Langan, SM, Di Meglio, P, Musters, AH, Prieto-Merino, D, Tsakok, T, Warren, RB, Flohr, C, Spuls, PI, Griffiths, CEM, Barker, J, Irvine, AD and Smith, CH (2020) Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 183 (2). 404 - 406.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Hampton, PJ, Reynolds, NJ, Smith, CH, Lunt, M, Griffiths, CEM and Warren, RB (2020) Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 183 (2). 294 - 302.

Pan, S, Tsakok, T, Dand, N, Lonsdale, DO, Loeff, FC, Bloem, K, de Vries, A, Baudry, D, Duckworth, M, Mahil, S, Pushpa-Rajah, A, Russell, A, Alsharqi, A, Becher, G, Murphy, R, Wahie, S, Wright, A, Griffiths, CEM, Reynolds, NJ, Barker, J, Warren, RB, David Burden, A, Rispens, T, Standing, JF, Smith, CH and Study Group, the BSTOP Study Group, the PSORT Consortium, BADBIR (2020) Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study. Clinical and Translational Science, 13 (2). 400 - 409.

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Grp, BADBIRS (2019) Risk of major cardiovascular events in adult patients with psoriasis treated with biologic therapies or methotrexate: Cohort study in the British Association of Dermatologists Biologic Interventions Register (BADBIR). Pharmacoepidemiology and Drug Safety, 27. 467 - 467.

Rungapiromnan, W, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, McElhone, K, Burden, AD, Rutter, MK, Warren, RB, Griffiths, CEM, Ashcroft, DM and Study Group, BADBIR (2019) Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 34 (4). 769 - 778.

Yiu, ZZN, Sorbe, C, Lunt, M, Rustenbach, SJ, Kühl, L, Augustin, M, Mason, KJ, Ashcroft, DM, Griffiths, CEM and Warren, RB (2019) Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 180 (4). 894 -901.

Yiu, ZZN, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Hampton, PJ, McElhone, K, Smith, CH, Warren, RB, Griffiths, CEM, Lunt, M, Burden, AD and Study Group, BADBIR (2019) A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and real-world populations in psoriasis. British Journal of Dermatology, 181 (6). 1265 - 1271.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Williams, S, Yiu, ZZN, McElhone, K, Ashcroft, DM, Kleyn, CE, Jabbar-Lopez, ZK, Owen, CM, Reynolds, NJ, Smith, CH, Wilson, N, Warren, RB and Griffiths, CEM (2019) Persistence and effectiveness of nonbiologic systemic therapies for moderate-to-severe psoriasis in adults: a systematic review. British Journal of Dermatology, 181 (2). 256 - 264.

Dand, N, Duckworth, M, Baudry, D, Russell, A, Curtis, CJ, Lee, SH, Evans, I, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Alsharqi, A, Becher, G, Burden, AD, Goodwin, RG, McKenna, K, Murphy, R, Perera, GK, Rotarescu, R, Wahie, S, Wright, A, Reynolds, NJ, Warren, RB, Griffiths, CEM, Smith, CH, Simpson, MA, Barker, JN, Study Group, BADBIR, Study Group, BSTOP and Consortium, PSORT (2018) HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 143 (6). 2120 - 2130.

Warren, RB, Marsden, A, Tomenson, B, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Soliman, MM, Burden, AD, Reynolds, NJ, Stocken, D, Emsley, R, Griffiths, CEM, Smith, C, Consortium, PSORT and Study Group, BADBIR (2018) Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 180 (5). 1069 - 1076.

Yiu, ZZN, Ashcroft, DM, Evans, I, McElhone, K ORCID: https://orcid.org/0000-0002-5419-0669, Lunt, M, Smith, CH, Walton, S, Murphy, R, Reynolds, NJ, Ormerod, AD, Griffiths, CEM, Warren, RB and Study Group, BADBIR (2018) Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 180 (2). 329 - 337.

Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Barker, JNWN, Smith, CH, Hampton, PJ, Lunt, M, McElhone, K, Warren, RB, Yiu, ZZN, Griffiths, CEM, Burden, AD and Study Group, BADBIR (2018) Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 154 (5). 581 - 588.

Thorneloe, RJ, Griffiths, CEM, Emsley, R, Ashcroft, DM, Cordingley, L, Interventions Register, British Association of Dermatologists Biologic and Relevant Therapy Study Group, Psoriasis Stratification to Optimise (2017) Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients' Medication Beliefs and Habit Strength. Journal of Investigative Dermatology, 138 (4). 785 - 794.

Iskandar, IYK, Warren, RB, Lunt, M, Mason, KJ ORCID: https://orcid.org/0000-0002-5419-0669, Evans, I, McElhone, K, Smith, CH, Reynolds, NJ, Ashcroft, DM, Griffiths, CEM and Study Group, BADBIR (2017) Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 138 (4). 775 - 784.

Rutter, MK, Kane, K, Lunt, M, Cordingley, L, Littlewood, A, Young, HS, Chew-Graham, CA, Hilton, R, Symmons, DPM and Griffiths, CEM (2016) Primary care-based screening for cardiovascular risk factors in patients with psoriasis. British Journal of Dermatology, 175 (2). 348 -356.

Nelson, PA, Barker, Z, Griffiths, CEM, Cordingley, L and Chew-Graham, CA (2013) 'On the surface': a qualitative study of GPs' and patients' perspectives on psoriasis. BMC Family Practice, 14. 158 -?.